-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lepunafusp Alfa in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lepunafusp Alfa in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lepunafusp Alfa in Mucopolysaccharidosis I...
-
Company Insights
Air France – Digital Transformation Strategies
Air France-KLM Digital Transformation Strategies Overview Air France has been focusing on using artificial intelligence, the Internet of Things (IoT), cloud-based mobile applications, big data, and drones to digitally transform its operations. The annual ICT spending of Air France was estimated at $911.8 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Air France-KLM is an international airline group specializing in air passenger transport, cargo transport, and aircraft maintenance....
-
Track & Monitor
Drones in defence: Aerial cargo delivery
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the defence industry’s Aerial cargo delivery segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Company Insights
NewPing An Insurance (Group) Company of China – Digital Transformation Strategies
Ping An Digital Transformation Strategies Overview The annual ICT spending of Ping An was estimated at $2.8 billion in 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. The following are some of the key highlights of the Ping An Insurance enterprise tech ecosystem: Ping An is tapping into the power of artificial intelligence (AI) to improve its business efficiency. AI, big data, cloud, and blockchain are among the key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Firicabtagene Autoleucel in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Firicabtagene Autoleucel in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Firicabtagene Autoleucel in Diffuse Large B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Firicabtagene Autoleucel in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Firicabtagene Autoleucel in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Firicabtagene Autoleucel in Follicular Lymphoma Drug Details: Firicabtagene autoleucel (CRG-022)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Firicabtagene Autoleucel in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Firicabtagene Autoleucel in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Firicabtagene Autoleucel in Relapsed Chronic Lymphocytic Leukemia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Firicabtagene Autoleucel in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Firicabtagene Autoleucel in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Firicabtagene Autoleucel in Refractory Chronic Lymphocytic Leukemia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Firicabtagene Autoleucel in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Firicabtagene Autoleucel in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Firicabtagene Autoleucel in Primary Mediastinal B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Firicabtagene Autoleucel in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Firicabtagene Autoleucel in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Firicabtagene Autoleucel in Marginal Zone B-cell Lymphoma Drug...